Goldman Sachs’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Goldman Sachs’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,226	Closed	-$449K	–	6027
2023 Q4	$449K	Buy	+1,226	New	+$19.2K	﹤0.01%	4820
2021 Q4	–	Sell	-1	Closed	-$52K	–	6855
2021 Q3	$52K	Buy	+1	New	+$58.5K	﹤0.01%	6044

Goldman Sachs's PBLA Position: Q1 2024 in Review

Goldman Sachs sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2024, closing a stake of 1,226 shares — an estimated $449K sold.

Goldman Sachs first reported a position in PBLA in Q3 2021 and held it in 2 quarters. The position peaked at $449K in Q4 2023. 0 funds tracked by Wall St. Rank hold PBLA as of Q1 2024.

Goldman Sachs reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Goldman Sachs sold 1,226 Panbela Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $449K.
Goldman Sachs first reported a position in Panbela Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
Goldman Sachs's Panbela Therapeutics, Inc. Common Stock position peaked at $449K in Q4 2023.
0 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.